Xuemin Xue
Overview
Explore the profile of Xuemin Xue including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
36
Citations
254
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Guo W, Zhou B, Dou L, Guo L, Li Y, Qin J, et al.
Exp Mol Med
. 2024 Dec;
57(1):59-71.
PMID: 39741182
Esophageal squamous cell carcinoma (ESCC) patients often face a grim prognosis due to lymph node metastasis. However, a comprehensive understanding of the cellular and molecular characteristics of metastatic lymph nodes...
2.
Zhu X, Nong L, Xue X, Feng X
Virchows Arch
. 2024 Dec;
PMID: 39630231
Due to the overlap of histological and molecular features of primary mediastinal large B-cell lymphoma (PMBL) with other lymphomas and its low incidence, the diagnosis and prognostic assessment of PMBL...
3.
Chen X, Qin Y, Xue X, Xie Z, Xie T, Huang L, et al.
Cancer Immunol Immunother
. 2024 Oct;
73(12):250.
PMID: 39358470
Patients with relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL) show varied responses to PD-1 monoclonal antibody (mAb) containing regimens. The mechanisms and predictive biomarkers for the efficacy of this regimen...
4.
Xue L, Li Y, Jiang L, Liu C, Cheng N, Guo C, et al.
J Natl Cancer Cent
. 2024 Sep;
4(2):162-168.
PMID: 39282585
Background: The prediction of response to immunotherapy mostly depends on the programmed death-ligand 1 (PD-L1) immunohistochemistry (IHC) status, and the 22C3 pharmDx assay has been approved in esophageal squamous cell...
5.
Xue X, Guo L, Guo C, Xu L, Li L, Yang L, et al.
Breast Cancer Res
. 2024 Sep;
26(1):128.
PMID: 39227982
Background: In 2022, our team launched the pioneering national proficiency testing (PT) scheme for the pathological diagnosis of breast cancer, rapidly establishing its credibility throughout China. Aiming to continuously monitor...
6.
Yuan P, Xue X, Qiu T, Ying J
Ther Adv Med Oncol
. 2024 Jan;
16:17588359231221910.
PMID: 38249331
alterations, including exon 14 skipping variants, amplification, overexpression, and fusion, play pivotal roles in primary tumorigenesis and acquired resistance to targeted therapies, especially tyrosine kinase inhibitors. They represent important diagnostic,...
7.
Xue X, Guo L, Guo C, Li L, Yang L, Wang X, et al.
BMC Cancer
. 2024 Jan;
24(1):23.
PMID: 38166768
Aim: Pathologists are currently supposed to be aware of both domestic and international guidelines for breast cancer diagnosis, but it is unclear how successfully these guidelines have been integrated into...
8.
Cao Z, Wang X, Xue X, Feng X
Ann Hematol
. 2023 Dec;
103(3):869-883.
PMID: 38040859
Peripheral T cell lymphoma, not otherwise specified (PTCL, NOS), is a heterogeneous and aggressive type of non-Hodgkin's lymphoma with a bleak prognosis. This study was designed to assess the value...
9.
Guo W, Zhou B, Bie F, Huai Q, Xue X, Guo L, et al.
Clin Transl Med
. 2023 Oct;
13(10):e1453.
PMID: 37846760
Introduction: With the advancements in early diagnosis, more and more patients with multiple primary lung cancer (MPLC) have been identified. However, the progression of MPLC involves complex changes in cell...
10.
Song J, Xu R, Zhang H, Xue X, Ruze R, Chen Y, et al.
Gastroenterology
. 2023 Sep;
165(6):1505-1521.e20.
PMID: 37657757
Background & Aims: Pancreatic ductal adenocarcinoma (PDAC) is a deadly malignancy with high intratumoral heterogeneity. There is a lack of effective therapeutics for PDAC. Entosis, a form of nonapoptotic regulated...